Immunicom Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 23

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 5

Immunicom General Information

Description

Developer of a therapeutic device intended for treating cancer, inflammatory and autoimmune diseases. The company develops a blood-filtering device that specializes in effectively treating a wide variety of cancer types, including those that have not responded to other treatment strategies, including other drug and biological-based immunotherapy options, with possibly fewer side effects, enabling physicians to directly attack cancer while enhancing the effects of other cancer treatments which may be used concurrently.

Contact Information

Website
www.immunicom.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 6048 Cornerstone Court West
  • Suite D
  • San Diego, CA 92121
  • United States
+1 (657)
Primary Industry
Therapeutic Devices
Other Industries
Biotechnology
Drug Discovery
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 6048 Cornerstone Court West
  • Suite D
  • San Diego, CA 92121
  • United States
+1 (657)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immunicom Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC Completed Clinical Trials - General
5. Grant 08-Jun-2022 Completed Clinical Trials - General
4. Debt - PPP 10-Apr-2020 Completed Startup
3. Later Stage VC (Series B) 01-Oct-2019 Completed Startup
2. Early Stage VC (Series B) 01-Nov-2015 $5M $9M Completed Startup
1. Early Stage VC (Series A) $4M $4M Completed Startup
To view Immunicom’s complete valuation and funding history, request access »

Immunicom Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series A
To view Immunicom’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Immunicom Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a therapeutic device intended for treating cancer, inflammatory and autoimmune diseases. The company develo
Therapeutic Devices
San Diego, CA
23 As of 2026

Antwerp, Belgium
 

Barcelona, Spain
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Immunicom Competitors (34)

One of Immunicom’s 34 competitors is Agomab Therapeutics, a Formerly VC-backed company based in Antwerp, Belgium.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Agomab Therapeutics Formerly VC-backed Antwerp, Belgium
Minoryx Venture Capital-Backed Barcelona, Spain
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Vertex Pharmaceuticals Formerly VC-backed Boston, MA
Cristal Therapeutics Venture Capital-Backed Maastricht, Netherlands
You’re viewing 5 of 34 competitors. Get the full list »

Immunicom Patents

  • 63

    Total Documents Applications and Grants

  • Total Patents Families

  • 18

    Granted

  • 8

    Pending

  • Expiring in next 12 mo

Immunicom Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024076704-A1 Il-6 removal Inactive 05-Oct-2022
AU-2022291929-A1 Modified tnf as a capture ligand Pending 17-Jun-2021
CA-3222835-A1 Modified tnf as a capture ligand Pending 17-Jun-2021
EP-4355381-A1 Modified tnf as a capture ligand Inactive 17-Jun-2021
JP-2024525352-A Modified tnf as a capture ligand Pending 17-Jun-2021 A61M1/362
To view Immunicom’s complete patent history, request access »

Immunicom Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immunicom Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Cancer Institute Government
National Institutes of Health Government
Zfounder Venture Capital Minority
Bootstrap Venture Partners Venture Capital Minority
Harlem River Navy Family Office Minority
To view Immunicom’s complete investors history, request access »

Ready to get started?

Request a free trial

Immunicom FAQs

  • When was Immunicom founded?

    Immunicom was founded in 2013.

  • Where is Immunicom headquartered?

    Immunicom is headquartered in San Diego, CA.

  • What is the size of Immunicom?

    Immunicom has 23 total employees.

  • What industry is Immunicom in?

    Immunicom’s primary industry is Therapeutic Devices.

  • Is Immunicom a private or public company?

    Immunicom is a Private company.

  • What is Immunicom’s current revenue?

    The current revenue for Immunicom is .

  • How much funding has Immunicom raised over time?

    Immunicom has raised $21.9M.

  • Who are Immunicom’s investors?

    National Cancer Institute, National Institutes of Health, Zfounder, Bootstrap Venture Partners, and Harlem River Navy have invested in Immunicom.

  • Who are Immunicom’s competitors?

    Agomab Therapeutics, Minoryx, Inovio Pharmaceuticals, Vertex Pharmaceuticals, and Cristal Therapeutics are some of the 34 competitors of Immunicom.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process